(Renaissance Capital's research analysts) Reata Pharmaceuticals, which is developing protein-based
antioxidant inflammation modulators (AIMs) for life-threatening diseases, filed
on Monday with the SEC to raise up to $80 million in an initial public
offering.
The Irving, TX-based company, which was founded in 2002 and
booked $51 million in sales for the 12 months ended September 30, 2015, plans
to list on the Nasdaq under the symbol RETA. Reata Pharmaceuticals filed
confidentially on 10/19/2015. Citi, Cowen & Company and Piper Jaffray are the
joint bookrunners on the deal. No pricing terms were disclosed.
Blogger Comment
Facebook Comment